All In Biotech

Free tool

FAERS Monitor: Cinvanti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209296 or its brand name (Cinvanti, Aprepitant). Reports on generic versions are filed under their own applications.

Reports

7,525

Serious

7,148

95% of reports

Hospitalization

4,493

Death reported

1,480

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue1,297
  • nausea1,128
  • pyrexia924
  • off label use889
  • alopecia825
  • dyspnoea824
  • diarrhoea784
  • rash768
  • vomiting714
  • hypersensitivity705
  • infusion related reaction695
  • pain693
  • decreased appetite689
  • stomatitis664
  • pruritus663

Reports by year received

View as table
YearReports
20047
200515
200628
200724
200829
200948
201066
2011105
2012141
2013169
2014160
2015228
2016393
2017164
2018362
2019447
2020508
2021677
2022642
2023763
20241,036
2025905
2026608

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,634 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
stomatitisSignal66430.928.719,044
infusion related reactionSignal69529.627.619,040
alopeciaSignal82511.811.18,176
hypersensitivitySignal70510.79.96,188
decreased appetiteSignal6898.37.74,461
pyrexiaSignal9247.57.05,254
rashSignal7684.94.62,450
pruritusSignal6634.84.52,043
fatigueSignal1,2974.74.43,865
vomitingSignal7144.24.01,809
dyspnoeaSignal8244.13.81,957
nauseaSignal1,1284.03.82,617
diarrhoeaSignal7843.43.21,364
painSignal6933.22.91,048
off label useSignal8892.82.71,102

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.